Rallybio Corporation
General ticker "RLYB" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $27.3M (TTM average)
Rallybio Corporation follows the US Stock Market performance with the rate: 17.2%.
Estimated limits based on current volatility of 1.9%: low 0.65$, high 0.68$
Factors to consider:
- Total employees count: 25 (-41.9%) as of 2024
- Top business risk factors: Product development delays, Regulatory and compliance, Market acceptance, Limited operating history, Sales and marketing challenges
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [0.66$, 1.94$]
- 2025-12-31 to 2026-12-31 estimated range: [0.74$, 2.06$]
Financial Metrics affecting the RLYB estimates:
- Positive: with PPE of -0.7 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -121.35 <= 0.33
- Positive: Investing cash flow per share per price, % of 82.47 > -0.66
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: negative Industry operating cash flow (median)
Short-term RLYB quotes
Long-term RLYB plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.64MM |
| Operating Expenses | $67.88MM | $78.93MM | $61.13MM |
| Operating Income | $-67.88MM | $-78.93MM | $-60.50MM |
| Non-Operating Income | $2.31MM | $6.41MM | $2.72MM |
| R&D Expense | $40.69MM | $53.54MM | $41.51MM |
| Income(Loss) | $-65.58MM | $-72.52MM | $-57.77MM |
| Profit(Loss)* | $-66.65MM | $-74.56MM | $-57.77MM |
| Stockholders Equity | $169.32MM | $106.18MM | $61.65MM |
| Assets | $180.44MM | $115.62MM | $68.11MM |
| Operating Cash Flow | $-57.28MM | $-60.27MM | $-49.28MM |
| Capital expenditure | $0.05MM | $0.01MM | $0.00MM |
| Investing Cash Flow | $-112.17MM | $27.66MM | $33.49MM |
| Financing Cash Flow | $51.08MM | $0.14MM | $5.20MM |
| Earnings Per Share** | $-2.09 | $-1.84 | $-1.33 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.